Qu Biologics Recruiting Crohn’s Patients in Canada for Phase 2 Trial, Hosting Webinar

Qu Biologics Recruiting Crohn’s Patients in Canada for Phase 2 Trial, Hosting Webinar
Qu Biologics has started enrolling patients in the RESTORE Phase 2 trial to evaluate its lead investigative immunotherapy, QBECO SSI, in patients with moderate to severe Crohn's disease. The study (NCT03472690) is recruiting up to 20 adult Crohn's patients at three sites in Canada — New Westminster, British Columbia; Vancouver, BC; and Hamilton, Ontario. To apply, patients will be asked 16 questions on a trial questionnaire that will assess their eligibility for the study. All participa
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *